Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CHEMOCENTRYX, INC.

(CCXI)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 30-09-2022
51.66 USD   -.--%
18/08Brits agentschap beveelt Tavneos-combo aan voor behandeling van zeldzame bloedvataandoening
MT
12/08Biotechaandelen vestigen hoop op opleving door M&A-stimulans
MR
10/08ChemoCentryx, Inc. : Stifel Nicolaus haalt aandeel van kooplijst
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op CHEMOCENTRYX, INC.
28/09Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease
20/09Chemocentryx, Inc. : Other Events (form 8-K)
25/08ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences
24/08ChemoCentryx Announces TAVNEOSģ (avacopan) Presentations at Upcoming Medical Conference..
18/08Insider Sell: Chemocentryx
18/08UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease
12/08Biotech stocks pin bounce back hopes on M&A boost
09/08Insider Sell: ChemoCentryx
09/08ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
09/08ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
09/08Insider Sell: ChemoCentryx
08/08CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
08/08ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended..
05/08Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Vo..
05/08MarketScreener’s World Press Review : August 5, 2022
05/08Coinbase & BlackRock unis, Amgen prend Chemocentryx..
04/08Healthcare Shares Slip Amid Deal News -- Healthcare Roundup
04/08Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition
04/08MÄRKTE USA/Wall Street uneinheitlich - Ölpreise im freien Fall
04/08Sector Update: Health Care Stocks Slipping Ahead of Thursday Close
04/08Sector Update: Health Care
04/08Amgen to Acquire Drugmaker ChemoCentryx in $3.7 Billion Deal
04/08Top Midday Gainers
04/08MÄRKTE USA/Wall Street konsolidiert Vortagesgewinne
04/08MÄRKTE USA/Börsen dürften etwas fester in den Handel starten
04/08Amgen : accord pour fera l'acquisition de ChemoCentryx
04/08ChemoCentryx Shares Soar Premarket on Amgen Takeover Deal
04/08Amgen to Acquire ChemoCentryx in $3.7 Billion Deal
04/08Chemocentryx, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure,..
04/08Amgen to buy ChemoCentryx for $3.7 billion
04/08Amgen to acquire chemocentryx for $4 billion in cash
04/08Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to a..
02/08ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, ..
02/08ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, ..
05/07Chemocentryx : Announces Appointment of Jennifer L. Herron to Board as Independent Directo..
05/07Chemocentryx, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, ..
05/07ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Direct..
05/07Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent ..
09/06Chemocentryx, Inc. : Change in Directors or Principal Officers (form 8-K)
09/06ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principa..
06/06ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Admi..
06/06ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Admi..
06/06Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally..
01/06Chemocentryx : Announces Changes to its Board of Directors - Form 8-K
01/06Chemocentryx, Inc. : Change in Directors or Principal Officers, Submission of Matters to a..
31/05ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferen..
31/05ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferen..
31/05ChemoCentryx Announces Changes to its Board of Directors
31/05ChemoCentryx Announces Changes to its Board of Directors
31/05ChemoCentryx Announces Changes to its Board of Directors
18/05ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meetin..
18/05ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meetin..
16/05ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
16/05ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
11/05ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOSģ (avacopan) and..
11/05ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOSģ (avacopan) and..
10/05CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
06/05ChemoCentryx Q1 Loss Widens as Revenue Declines
05/05Chemocentryx : Q1 Earnings Snapshot
05/05Transcript : ChemoCentryx, Inc., Q1 2022 Earnings Call, May 05, 2022
05/05Earnings Flash (CCXI) CHEMOCENTRYX Posts Q1 Revenue $5.46M
05/05ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
05/05ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
05/05ChemoCentryx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
03/05Chemocentryx, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
28/04ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, ..
13/04ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I T..
13/04ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Pha..
02/03CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
01/03Transcript : ChemoCentryx, Inc., Q4 2021 Earnings Call, Mar 01, 2022
01/03Chemocentryx : Reports Fourth Quarter and Full Year 2021 Financial Results and Recent High..
01/03ChemoCentryx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
01/03Chemocentryx : Q4 Earnings Snapshot
01/03Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Revenue $2.3M, vs. Street Est of $3.9M
01/03Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Loss $-0.58, vs. Street Est of $-0.58
01/03ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Hig..
28/02Chemocentryx, Inc. : Change in Directors or Principal Officers (form 8-K)
23/02ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Cal..
09/02ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
20/01ChemoCentryx Announces EU Approval of TAVNEOS (avacopan) for the Treatment of ANCA-Asso..
19/01ChemoCentryx Secures EU Approval for Vasculitis Treatment
19/01ChemoCentryx Announces EU Approval of TAVNEOSģ (avacopan) for the Treatment of ANCA-Ass..
19/01ChemoCentryx, Inc Announces EU Approval of Tavneosģ for the Treatment of ANCA-Associate..
19/01Vifor: feu vert européen pour Tavneos contre des vasculites
12/01Chemocentryx : Corporate Presentation January 2022
12/01Transcript : ChemoCentryx, Inc. Presents at JPMorgan 40th Annual Healthcare C..
04/01ChemoCentryx to Present at Two Upcoming Investor Conferences
2021Insider Sell: Chemocentryx
2021ChemoCentryx, Inc. - Positive Recommendation for Use of TAVNEOS (avacopan) in ANCA Vasc..
2021Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted ..
2021ChemoCentryx Says European Medicines Agency Recommends Tavneos Marketing Authorization
2021Chemocentryx, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhi..
2021Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted..
2021ChemoCentryx, Inc Announces Positive Recommendation for Use of TAVNEOS? in ANCA Vasculi..
2021Vifor: VFMCRP décroche une recommandation du CHMP pour Tavneos
2021ChemoCentryx Narrows Q3 Loss on Rising Revenue; Stock Rises
2021ChemoCentryx to Participate in Two Upcoming Investor Conferences
2021ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights - Form ..
2021Transcript : ChemoCentryx, Inc., Q3 2021 Earnings Call, Nov 09, 2021
2021Chemocentryx : Q3 Earnings Snapshot
Volgende evenement op CHEMOCENTRYX, INC.